Antiepileptic Drugs

  • Hans-Hasso Frey
  • Dieter Janz

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 74)

Table of contents

  1. Front Matter
    Pages I-XXII
  2. Clinical Aspects of Epileptic Disease

    1. Front Matter
      Pages 1-1
    2. R. Hess
      Pages 35-54
    3. T. A. Holliday
      Pages 55-76
  3. Pathophysiology of Seizure Disorders

    1. Front Matter
      Pages 77-77
    2. B. E. Dwyer, C. G. Wasterlain
      Pages 79-100
    3. C. Bianchi, L. Beani
      Pages 139-151
    4. B. S. Meldrum
      Pages 153-188
    5. K. Wiśniewski, H.-H. Frey
      Pages 189-195
  4. General Pharmacology of Antiepileptic Drugs

    1. Front Matter
      Pages 197-197
    2. G. L. Jones, D. M. Woodbury
      Pages 245-263
    3. H.-H. Frey
      Pages 265-282
    4. W. P. Koella, G. D. Gladding, H. J. Kupferberg, E. A. Swinyard
      Pages 283-347
  5. Specific Pharmacology of Antiepileptic Drugs

    1. Front Matter
      Pages 349-349
    2. G. L. Jones, G. H. Wimbish
      Pages 351-419
    3. B. B. Gallagher, L. S. Freer
      Pages 421-447
    4. H.-H. Frey
      Pages 449-477
    5. M. Schmutz
      Pages 479-506
    6. W. Löscher
      Pages 507-536
    7. R. Kretzschmar, H. J. Teschendorf
      Pages 537-555
    8. H. J. Teschendorf, R. Kretzschmar
      Pages 557-574
    9. S. Caccia, S. Garattini
      Pages 575-593
    10. J. E. Riggs, R. C. Griggs
      Pages 595-600
    11. E. A. Swinyard
      Pages 601-610
  6. Clinical Pharmacology of Antiepileptic Drugs

    1. Front Matter
      Pages 659-659
    2. E. Perucca, A. Richens
      Pages 661-723
    3. E. F. Hvidberg
      Pages 725-764
    4. M. J. Eadie
      Pages 765-790
    5. D. Schmidt
      Pages 791-829
    6. E. Perucca, A. Richens
      Pages 831-855
  7. Back Matter
    Pages 857-870

About this book


Epileptic disorders need treatment for many years or even for life, and this makes a thorough understanding of the pharmacokinetics and possible hazards and side effects of the drugs used in treatment mandatory. During recent decades our knowledge in this field has considerably increased, not least as a result of the development of specific and sensitive methods for the determination of anti­ epileptic agents in biological material. The clinical pharmacology of this group of drugs has been studied extensively and can today be regarded as well established. This does not necessarily mean that drug treatment of epilepsy is without problems. For example, it has recently been shown that one of the newer anti­ epileptic drugs, greeted with great enthusiasm by clinicians, may in rare instances induce serious damage to the liver and the pancreas, and seems even to have a certain teratogenic potential. Clinical problems should be understood as a challenge to the experimental pharmacologist, who should try to find explanations for the clinical hazards, and, if possible, show new ways in which better drugs might be developed. In recent years interest has focused on the importance of the inhibitory transmitter 'l'-aminobutyric acid (GABA) in the pathophysiology of epilepsy, and there have been a series of attempts to find useful antiepileptic drugs among substances interfering with GABA metabolism in the CNS.


CNS Drugs GABA drug kinetics metabolism pathophysiology pharmacokinetics pharmacology physiology

Editors and affiliations

  • Hans-Hasso Frey
    • 1
  • Dieter Janz
    • 2
  1. 1.Laboratorium für Pharmakologie und Toxikologie Fachbereich VeterinärmedizinFreie Universität BerlinGermany
  2. 2.Abteilung für NeurologieKlinikum CharlottenburgGermany

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1985
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-69520-9
  • Online ISBN 978-3-642-69518-6
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods